--- title: "Cardiff Oncology (CRDF) news: offering, lawsuit and settlement" url: "https://aibio.space/companies/cardiff-oncology/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "CRDF offering, lawsuit and settlement news: Cardiff Oncology prices $40 million share offering at $2.60, above last sale. Cardiff Oncology, Inc." --- CRDF Cardiff Oncology, Inc. NASDAQ · United States # Cardiff Oncology (CRDF) news CRDF offering, lawsuit and settlement news Legal · 2026-09-14 ## [Cardiff Oncology settles onvansertib license lawsuit with Nerviano Medical Sciences](https://aibio.space/news/cardiff-oncology-settles-onvansertib-license-lawsuit-nerviano-medical/) Cardiff Oncology settled its lawsuit against Nerviano Medical Sciences, the licensor of its lead drug onvansertib, on September 14, 2026. The case is dismissed with prejudice and the license is amended. Nerviano was the only defendant in the suit. ## Latest Cardiff Oncology news 1. 2026-05-29 Legal [Cardiff Oncology disputes Nerviano's termination of 2017 license agreement](https://aibio.space/news/cardiff-oncology-disputes-nervianos-termination-2017-license-agreement/) Nerviano Medical Sciences told Cardiff on May 27, 2026 it was ending the License Agreement over a patent inventorship dispute. Cardiff, which sued NMS as defendant on May 19, says the notice is legally ineffective. 2. 2024-12-10 Financings [Cardiff Oncology prices $40 million share offering at $2.60, above last sale](https://aibio.space/news/cardiff-oncology-prices-40-million-share-offering-2-60-above-last-sale/) The company is selling 15,384,619 shares. The stock last traded at $2.44 on December 9, 2024. Cardiff plans to use proceeds for onvansertib trials in colorectal cancer. ## Cardiff Oncology at a glance - **Ticker**: CRDF - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $34.5 million ### Related companies - [Anika Therapeutics](https://aibio.space/companies/anika-therapeutics/) NASDAQ: ANIK - [RenovoRx](https://aibio.space/companies/renovorx/) NASDAQ: RNXT - [Rockwell Medical](https://aibio.space/companies/rockwell-medical/) NASDAQ: RMTI - [Bone Biologics](https://aibio.space/companies/bone-biologics/) NASDAQ: BBLG - [MiMedx Group](https://aibio.space/companies/mimedx/) NASDAQ: MDXG - [Dermata Therapeutics](https://aibio.space/companies/dermata-therapeutics/) NASDAQ: DRMA - [Endovia Health Sciences](https://aibio.space/companies/endovia-health-sciences/) AMEX: EDVA - [Alpha Cognition](https://aibio.space/companies/alpha-cognition/) NASDAQ: ACOG ### Also on NASDAQ - [Royalty Pharma](https://aibio.space/companies/royalty-pharma/) RPRX - [Biofrontera](https://aibio.space/companies/biofrontera-bfri/) BFRI - [Glucotrack](https://aibio.space/companies/glucotrack/) GCTK - [AnaptysBio](https://aibio.space/companies/anaptysbio/) ANAB - [SS Innovations International](https://aibio.space/companies/ss-innovations-international/) SSII - [Biomea Fusion](https://aibio.space/companies/biomea-fusion/) BMEA ## Cardiff Oncology annual financials | Line | FY2025 | FY2024 | |---|---|---| | Net income (loss) | [-$45.9 million](https://www.sec.gov/Archives/edgar/data/1213037/000119312526067464/) | [-$45.4 million](https://www.sec.gov/Archives/edgar/data/1213037/000119312526067464/) | | Cash from operations | [-$37.9 million](https://www.sec.gov/Archives/edgar/data/1213037/000119312526067464/) | [-$37.7 million](https://www.sec.gov/Archives/edgar/data/1213037/000119312526067464/) | | Cash and equivalents | [$17.5 million](https://www.sec.gov/Archives/edgar/data/1213037/000119312526344545/) | [$51.5 million](https://www.sec.gov/Archives/edgar/data/1213037/000119312526067464/) | | Short-term investments | [$40.8 million](https://www.sec.gov/Archives/edgar/data/1213037/000119312526344545/) | [$40.3 million](https://www.sec.gov/Archives/edgar/data/1213037/000119312526067464/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $9.2 million, plus short-term investments of $25.3 million, $34.5 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Cardiff Oncology Has Cardiff Oncology raised money recently? Our latest story on this, dated Dec 10, 2024: "Cardiff Oncology prices $40 million share offering at $2.60, above last sale". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/cardiff-oncology-prices-40-million-share-offering-2-60-above-last-sale/). Is Cardiff Oncology involved in a lawsuit? Our latest story on this, dated Sep 14, 2026: "Cardiff Oncology settles onvansertib license lawsuit with Nerviano Medical Sciences". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/cardiff-oncology-settles-onvansertib-license-lawsuit-nerviano-medical/). Has Cardiff Oncology settled a lawsuit? Our latest story on this, dated Sep 14, 2026: "Cardiff Oncology settles onvansertib license lawsuit with Nerviano Medical Sciences". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/cardiff-oncology-settles-onvansertib-license-lawsuit-nerviano-medical/). What is the ticker symbol of Cardiff Oncology? Cardiff Oncology, Inc. trades under the ticker CRDF on NASDAQ. Where is Cardiff Oncology listed? Cardiff Oncology, Inc. is listed on NASDAQ. What is the SEC CIK of Cardiff Oncology? The SEC Central Index Key (CIK) for Cardiff Oncology, Inc. is 1213037. Its filings are on SEC EDGAR. How many shares does Cardiff Oncology have outstanding? 77,795,249 shares as of 2026-08-06, per the cover page of its 10-Q filed 2026-08-11. Which country or territory is Cardiff Oncology listed under? Our directory records Cardiff Oncology, Inc. under United States. What does Cardiff Oncology do? Our directory classifies Cardiff Oncology, Inc. as: Biopharma / pharmaceuticals. This is a directory classification, not a description of the pipeline. What is the ISIN of Cardiff Oncology? The ISIN recorded for Cardiff Oncology, Inc. is US14147L1089. Does aibio.space cover Cardiff Oncology? aibio.space lists Cardiff Oncology, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Cardiff Oncology incorporated? SEC records list its state or country of incorporation as DE. Is Cardiff Oncology profitable? Cardiff Oncology, Inc. reported a net loss of $45.9 million for the fiscal year ended Dec 31, 2025, and used $37.9 million of cash in operations, per its annual report to the SEC. How much cash does Cardiff Oncology have? $34.5 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. What is the latest Cardiff Oncology (CRDF) stock news? Our latest story on Cardiff Oncology, dated Sep 14, 2026: "Cardiff Oncology settles onvansertib license lawsuit with Nerviano Medical Sciences". Cardiff Oncology settled its lawsuit against Nerviano Medical Sciences, the licensor of its lead drug onvansertib, on September 14, 2026. The case is dismissed with prejudice and the license is amended. Nerviano was the only defendant in the suit. [Source](https://aibio.space/news/cardiff-oncology-settles-onvansertib-license-lawsuit-nerviano-medical/). ## Investor discussion: Cardiff Oncology Members talk about Cardiff Oncology (CRDF). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Cardiff Oncology, newest first. Each line links the filing it comes from. 1. 2026-10-22 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/1213037/000149315226048111/form8-k.htm) 2. 2026-07-16 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1213037/000119312526305465/crdf_07.14.26_-_424b5.htm) 3. 2026-04-09 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1213037/000119312526149623/crdf-ex99_1.htm) 4. 2026-02-24 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1213037/000119312526067464/crdf-20251231.htm) 5. 2026-02-24 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1213037/000119312526067476/crdf-ex99_1.htm) 6. 2025-06-17 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 5.02,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1213037/000095017025087369/crdf-ex99_1.htm) 7. 2025-02-27 Financings Set up an at-the-market program to sell shares over time. SEC Form S-3. [Source](https://www.sec.gov/Archives/edgar/data/1213037/000095017025029044/crdf_s-3_2.27.25.htm) 8. 2024-12-10 Financings Reported a financing. SEC Form 8-K (Items 1.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1213037/000095017024134970/crdf-ex99_1.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:CRDF on TradingView](https://www.tradingview.com/symbols/NASDAQ-CRDF/). ## SEC filings and registration - **SEC name**: Cardiff Oncology, Inc. - **CIK**: 1213037 - **Industry (SIC)**: Biological Products, (No Diagnostic Substances) (2836) - **US tickers**: CRDF (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 11055 FLINTKOTE AVENUE, SAN DIEGO, CA, 92121 - **Phone**: 858-952-7570 - **Shares outstanding**: 77,795,249 as of 2026-08-06 (10-Q filed 2026-08-11) - **Former names**: Trovagene, Inc.; TrovaGene Inc.; XENOMICS INC ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/1213037/000149315226048111/form8-k.htm) filed 2026-10-22 - [8-K](https://www.sec.gov/Archives/edgar/data/1213037/000149315226042506/form8-k.htm) filed 2026-09-14 - [DEF 14A](https://www.sec.gov/Archives/edgar/data/1213037/000119312526368249/crdf_def_14a_special_pro.htm) filed 2026-08-26 - [8-K](https://www.sec.gov/Archives/edgar/data/1213037/000119312526344645/crdf-20260811.htm) filed 2026-08-11 - [10-Q](https://www.sec.gov/Archives/edgar/data/1213037/000119312526344545/crdf-20260630.htm) filed 2026-08-11 - [8-K](https://www.sec.gov/Archives/edgar/data/1213037/000119312526305467/crdf-20260714.htm) filed 2026-07-16 - [424B5](https://www.sec.gov/Archives/edgar/data/1213037/000119312526305465/crdf_07.14.26_-_424b5.htm) filed 2026-07-16 - [8-K](https://www.sec.gov/Archives/edgar/data/1213037/000119312526267563/crdf-20260611.htm) filed 2026-06-11 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001213037), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Cardiff Oncology, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker CRDF, recorded under United States. The directory classifies it as Biopharma / pharmaceuticals. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Cardiff Oncology, Inc. - **Ticker**: CRDF - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Biopharma / pharmaceuticals - **ISIN**: US14147L1089 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-CRDF/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/cardiff-oncology/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Cardiff Oncology (CRDF) news: offering, lawsuit and settlement", 2026-10-31, https://aibio.space/companies/cardiff-oncology/